Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Scott T. Hall"'
Autor:
Raymund R. Razonable, John C. O’Horo, Douglas W. Challener, Lori Arndt, Richard F. Arndt, Caroline G. Clune, Tracy L. Culbertson, Scott T. Hall, Alexander Heyliger, Tammy A. Jackson, Brian D. Kennedy, Jennifer Larsen, Sara N. Hanson, Perry W. Sweeten, Sidna M. Tulledge-Scheitel, Ravindra Ganesh
Publikováno v:
Mayo Clinic Proceedings. 97:1641-1648
Autor:
Jennifer Nelson, Nathan L Woolever, Lisa M Meyer, Scott T Hall, Jaclyn Stakston, Ala Dababneh, Michael Van Sistine, Jennifer M Tempelis, Ross Dierkhising, Sarah R Lessard, Kathleen Roush
Publikováno v:
Open Forum Infectious Diseases. 9
Background Sexual assault survivors are at increased risk for sexually transmitted infections. Due to patient vulnerability, institutions have implemented Sexual Assault Nurse Examiner (SANE) protocols to care for these patients. These protocols guid
Publikováno v:
World Journal of Surgery. 46:98-103
Ketorolac is an effective analgesic but the potential for acute kidney injury (AKI) is concerning, particularly in geriatric “G-60 trauma” patients. The objectives of this study are to report the incidence of AKI in patients who receive ketorolac
Autor:
Raymund R Razonable, John C O’Horo, Sara N Hanson, Richard F Arndt, Leigh L Speicher, Teresa A Seville, Scott T Hall, Marsha L Pike, Alexander Heyliger, Jennifer J Larsen, Ravindra Ganesh, Sidna M Tulledge-Scheitel
Publikováno v:
The Journal of infectious diseases. 226(10)
The effectiveness of bebtelovimab in real-world settings has not been assessed. In this retrospective cohort study of 3607 high-risk patients, bebtelovimab was used more commonly than nirmatrelvir-ritonavir for treatment of coronavirus disease 2019 (
Autor:
Jeffrey F. Barletta, Kyle C Molina, Alicia Mangram, Scott T Hall, James K. Dzandu, Vanthida Huang
Publikováno v:
Surgical Infections. 21:43-47
Background: The Augmented Renal Clearance in Trauma Intensive Care (ARCTIC) scoring system is a validated system to predict augmented renal clearance in trauma patients. This study examined the abi...
Autor:
Jeffrey F. Barletta, Alicia Mangram, Scott T Hall, Jennifer A. Frontera, Diana Abdul-Rahman, Victor Zach, James K. Dzandu
Publikováno v:
Neurocritical Care. 33:405-413
Desmopressin (DDAVP) has been suggested for antiplatelet medication reversal in patients with traumatic brain injury (TBI) but there are limited data describing its effect on clinical outcomes. The purpose of this study was to evaluate the effect of
Autor:
Raymund R, Razonable, John C, O'Horo, Douglas W, Challener, Lori, Arndt, Richard F, Arndt, Caroline G, Clune, Tracy L, Culbertson, Scott T, Hall, Alexander, Heyliger, Tammy A, Jackson, Brian D, Kennedy, Jennifer, Larsen, Sara N, Hanson, Perry W, Sweeten, Sidna M, Tulledge-Scheitel, Ravindra, Ganesh
Publikováno v:
Mayo Clinic proceedings. 97(9)
To describe and compare the clinical outcomes of bamlanivimab-etesevimab, casirivimab-imdevimab, and sotrovimab treatment of mild to moderate coronavirus disease 2019 (COVID-19) during the severe acute respiratory coronavirus 2 (SARS-CoV-2) B.1.617.2
Autor:
John O’Horo, Douglas W. Challener, Ryan J. Anderson, Richard F. Arndt, Sara E. Ausman, Scott T. Hall, Alexander Heyliger, Brian D. Kennedy, Perry W. Sweeten, Ravindra Ganesh, Raymund R. Razonable
Publikováno v:
Mayo Clinic proceedings. 97(5)
Bamlanivimab-etesevimab and casirivimab-imdevimab are authorized by the US Food and Drug Administration for emergency treatment of mild to moderate coronavirus disease 2019 (COVID-19) in high-risk persons. There has been no study comparing their clin
Publikováno v:
World journal of surgery. 46(1)
Ketorolac is an effective analgesic but the potential for acute kidney injury (AKI) is concerning, particularly in geriatric "G-60 trauma" patients. The objectives of this study are to report the incidence of AKI in patients who receive ketorolac, id
Publikováno v:
Journal of Intensive Care Medicine. 35:1434-1438
Purpose: The objective of this study was to compare the incidence of acute kidney injury (AKI) among critically ill patients receiving combination therapy with vancomycin plus piperacillin–tazobactam (VPT) against patients receiving vancomycin plus